Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

NCT01201837 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

507

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Coronary Syndrome

Interventions

DRUG: Placebo
DRUG: CER-001

Sponsor

Cerenis Therapeutics, SA